📰 Interval Prolongation News
Page 2 - Interval Prolongation News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Interval Prolongation. Real-time updates on events, politics, business and more.
December 11, 2021
TIBSOVO in combination with azacitidine compared to placebo plus azacitidine also demonstrated significant improvements in complete remission rate, complete remission and complete remission
November 4, 2021
/PRNewswire/ -- Servier, a growing leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced new data in acute...
November 4, 2021
/PRNewswire/ -- Servier, a growing leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced new data in acute...
May 5, 2021
Share this article Share this article BOSTON, May 5, 2021 /PRNewswire/ -- Servier Pharmaceuticals, a growing leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and Drug Administration (FDA) has accepted the companys supplemental New Drug Application (sNDA) for TIBSOVO (ivosidenib tablets) as a potential treatment for patients with previously treated IDH1-mutated cholangiocarcinoma. The sNDA was granted Priority Review,...
January 17, 2021
Home / Top News / Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma – Supplemental New Drug Application Planned for Submission in Q1 2021 – CAMBRIDGE, Mass., Jan. 17, 2021 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO),...
January 17, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in ... Agios Pharmaceuticals, Inc.January 17, 2021 GMT CAMBRIDGE, Mass., Jan. 17, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today reported a full analysis of the final data, including mature over...